SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Safety and Efficacy Measures with Both CYPHER Stent and Xience Stent BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Investigators reported ...

March 7, 2005 (Orlando) -- Opening day of the American College of Cardiology 2005 Annual Scientific Sessions was dominated by news about drug-eluting stents, and at the end of the day, "it was clearly ...

New data from a Spanish study presented at the 2005 American Heart Association Scientific Sessions found that patients with bifurcation lesions fared significantly better when treated with the CYPHER® ...

Milan, Italy - A study evaluating the safety and effectiveness of stretching the six-cell sirolimus-eluting stent (Cypher, Cordis/Johnson & Johnson) beyond its intended diameter with a 3.5- to 4.0-mm ...

ATLANTA -- March 11, 2006 -– Patients treated with the CYPHER® Sirolimus-eluting Coronary Stent continued to experience significantly better long-term clinical outcomes than those who received a bare ...

At this year's annual meeting of the American College of Cardiology (ACC; Bethesda, MD), the confluence of three major comparative studies of drug-eluting coronary stents led industry observers to dub ...

BOSTON (MarketWatch) -- Johnson & Johnson said early Monday that a 15-month study has found that patients who received its Cypher drug-coated stent had a lower risk of developing blood clots after the ...

SAN FRANCISCO (MarketWatch) -- Cordis, a divison of Johnson & Johnson , said Monday the Food and Drug Administration has approved revised instructions for use of its Cypher sirolimus-eluting coronary ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER® ...

Reason for posting: The use of coronary stents has improved the results of percutaneous coronary revascularization procedures. Along with newer antithrombotic therapy using glycoprotein IIb/IIIa ...

WASHINGTON--(BUSINESS WIRE)--In the first six-year follow-up of a pivotal study of any drug-eluting stent, the clinical benefits of the CYPHER ® Sirolimus-eluting Coronary Stent compared to a ...